105 related articles for article (PubMed ID: 23053256)
1. Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas.
Bernstein-Molho R; Kollender Y; Issakov J; Bickels J; Dadia S; Flusser G; Meller I; Sagi-Eisenberg R; Merimsky O
Cancer Chemother Pharmacol; 2012 Dec; 70(6):855-60. PubMed ID: 23053256
[TBL] [Abstract][Full Text] [Related]
2. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma.
Gebbia V; Boussen H; Valerio MR
Anticancer Res; 2012 Feb; 32(2):529-36. PubMed ID: 22287742
[TBL] [Abstract][Full Text] [Related]
3. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy and P-glycoprotein expression in chondrosarcoma.
Terek RM; Schwartz GK; Devaney K; Glantz L; Mak S; Healey JH; Albino AP
J Orthop Res; 1998 Sep; 16(5):585-90. PubMed ID: 9820282
[TBL] [Abstract][Full Text] [Related]
5. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
[TBL] [Abstract][Full Text] [Related]
6. A role for maintenance therapy in managing sarcoma.
Ray-Coquard I; Le Cesne A
Cancer Treat Rev; 2012 Aug; 38(5):368-78. PubMed ID: 21843915
[TBL] [Abstract][Full Text] [Related]
7. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
8. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
9. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study.
Grignani G; Palmerini E; Stacchiotti S; Boglione A; Ferraresi V; Frustaci S; Comandone A; Casali PG; Ferrari S; Aglietta M
Cancer; 2011 Feb; 117(4):826-31. PubMed ID: 20925044
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma.
Schuetze SM; Zhao L; Chugh R; Thomas DG; Lucas DR; Metko G; Zalupski MM; Baker LH
Eur J Cancer; 2012 Jun; 48(9):1347-53. PubMed ID: 22525224
[TBL] [Abstract][Full Text] [Related]
13. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine: a single-center experience.
Deutschbein T; Matuszczyk A; Moeller LC; Unger N; Yuece A; Lahner H; Mann K; Petersenn S
Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):540-3. PubMed ID: 21667440
[TBL] [Abstract][Full Text] [Related]
15. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
16. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
17. Targeting the mammalian target of rapamycin in myxoid chondrosarcoma.
Merimsky O; Bernstein-Molho R; Sagi-Eisenberg R
Anticancer Drugs; 2008 Nov; 19(10):1019-21. PubMed ID: 18827568
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma.
Oza AM; Pignata S; Poveda A; McCormack M; Clamp A; Schwartz B; Cheng J; Li X; Campbell K; Dodion P; Haluska FG
J Clin Oncol; 2015 Nov; 33(31):3576-82. PubMed ID: 26077241
[TBL] [Abstract][Full Text] [Related]
19. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
[TBL] [Abstract][Full Text] [Related]
20. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
